NASDAQ:BCAB

Bioatla Stock News

Healthcare > Biotechnology

Buy BCAB

*Your capital is at risk

$3.29

-0.0900 (-2.66%)

At Close: Jul 31, 2026

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

06:12am, Tuesday, 08'th Oct 2024

BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company fa

BioAtla: Numerous Catalysts Coming In Q4

11:29am, Monday, 07'th Oct 2024

BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla fa

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

09:05am, Friday, 04'th Oct 2024

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther

Michael Burry buys 634,000 shares of this $1 penny stock

09:19am, Tuesday, 01'st Oct 2024

When Michael Burry, the man who famously bet against the housing market before the 2008 financial crash, makes a move, investors take notice.

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

08:00am, Tuesday, 01'st Oct 2024

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

07:30am, Monday, 23'rd Sep 2024

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and comm

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

01:32am, Sunday, 11'th Aug 2024

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Wa

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

05:39pm, Thursday, 25'th Jul 2024

SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther

3 Penny Stocks With 735% Average Upside, According to Wall Street

10:47am, Tuesday, 09'th Jul 2024

With the third quarter in full swing, the bulls have not lost their grip on equities.

BioAtla to Participate in the Jefferies Global Healthcare Conference

08:00am, Wednesday, 29'th May 2024

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

05:05pm, Thursday, 23'rd May 2024

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by